What this means
PhenoAge, a blood-based biological aging clock, is associated with cancer outcomes, a finding taken as evidence that biological aging shapes prognosis. In 3,067 patients undergoing primary tumor resection, PhenoAge acceleration rose with tumor stage.
A plain-English summary is on its way. Until then, this is the start of the authors' own summary.
- Who it was tested in
- Not stated
- Kind of research
- Early results, not yet checked by other scientists
The science
- Original title
- Blood-based PhenoAge may reflect disease burden rather than biological aging in cancer
- Authors
- Simhal, A. K., Lee, J., Tan, K. S. et al.
- Journal
- medRxiv (preprint, not yet peer reviewed)
- Published
- Oct 19, 2026
- Study type
- Preprint
Abstract
PhenoAge, a blood-based biological aging clock, is associated with cancer outcomes, a finding taken as evidence that biological aging shapes prognosis. In 3,067 patients undergoing primary tumor resection, PhenoAge acceleration rose with tumor stage. One or two of its eight blood components, differing by cancer type, carried the prognostic signal, and replacing its general-population weights with equal weights did not weaken it. In cancer, PhenoAge may reflect disease burden rather than biological aging.
Simhal, A. K., Lee, J., Tan, K. S. et al. Blood-based PhenoAge may reflect disease burden rather than biological aging in cancer. medRxiv. 2026. doi:10.64898/2026.10.15.26365671. https://doi.org/10.64898/2026.10.15.26365671